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Abstract The very rapid worldwide increase in mobile
phone use in the last decade has generated considerable
interest in the possible health effects of exposure to radio
frequency (RF) fields. A multinational case–control study,
INTERPHONE, was set-up to investigate whether mobile
phone use increases the risk of cancer and, more specifi-
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cally, whether the RF fields emitted by mobile phones are
carcinogenic. The study focused on tumours arising in the
tissues most exposed to RF fields from mobile phones:
glioma, meningioma, acoustic neurinoma and parotid gland
tumours. In addition to a detailed history of mobile phone
use, information was collected on a number of known and
potential risk factors for these tumours. The study was
conducted in 13 countries. Australia, Canada, Denmark,
Finland, France, Germany, Israel, Italy, Japan, New Zea-
land, Norway, Sweden, and the UK using a common core
protocol. This paper describes the study design and meth-
ods and the main characteristics of the study population.
INTERPHONE is the largest case–control study to date
investigating risks related to mobile phone use and to other
potential risk factors for the tumours of interest and in-
cludes 2,765 glioma, 2,425 meningioma, 1,121 acoustic
neurinoma, 109 malignant parotid gland tumour cases and
7,658 controls. Particular attention was paid to estimating
the amount and direction of potential recall and participa-
tion biases and their impact on the study results.
Keywords Mobile phones  Case–control  Methods 
Study design  Cancer  Benign tumours  Brain tumours 
Acoustic neurinoma  Parotid gland tumours
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Introduction
It is estimated that there are now over 2 billion mobile
phone users in the world, and this number continues to
increase [1]. Widespread concern that exposure to RF fields
emitted by mobile phones may have an impact on health
has accompanied the dramatic increase in use of these
phones worldwide [2].
In the late 1990’s, several expert groups critically re-
viewed the available evidence concerning the possible
health effects of low-level exposures to RF fields and
recommended that research be carried out to determine
whether mobile (also called cellular) phones could cause
adverse health effects [3–6].
As a result, a feasibility study was carried out in four-
teen countries, coordinated by the International Agency for
Research on Cancer (IARC) in Lyon. It was concluded that
an international study of the relation between mobile phone
use and risk of adult head and neck tumours, including
brain tumours, would be both feasible and informative [7],
while studies of these relatively rare tumours in single
countries would generally lack sufficient statistical power.
Thus INTERPHONE was initiated as a set of multi-na-
tional case–control studies, focusing on four types of tu-
mour: glioma, meningioma, acoustic neurinoma and
parotid gland tumours.
Since the beginning of INTERPHONE, the results of a
number of other studies on the risk of head and neck tu-
mours in relation to mobile phone use have been published.
These include both cohort and case–control studies [8–16].
To date, however, the evidence remains inconclusive about
a possible association between mobile phone use and the
risk of cancer.
The current paper presents the design, detailed methods,
and description of the study population in all the partici-
pating centres of INTERPHONE. Some of these centres
have already published results [17–38].
Separate papers, based on the full international IN-
TERPHONE study, will address (1) the possible relation-
ship between the risk of these tumours and mobile phone
use; (2) the possible relationship between the risk of these
tumours and estimated RF exposure from mobile phone
use; (3) the contributions to tumour risk of other possible
risk factors.
Objectives
The primary objective of INTERPHONE was to investigate
whether mobile phone use increases the risk of tumours
and, specifically, whether RF fields emitted by mobile
phones are tumourigenic.
Most of the RF absorbed energy from mobile phone use
is absorbed in the immediate vicinity of the handset, in a
volume of about 5 cm3 in the head. Of this, most is ab-
sorbed by the skin, the salivary glands (particularly the
parotid gland) and the external ear; only 20–30% is ab-
sorbed by the brain as a whole [39]. In the brain, absorbed
energy is highest for glial and meningeal tissue located in
the outermost part of the frontal, parietal and temporal
lobes on the side of the head where the phone is used [39–
41]. The tumour types selected for study are those that
occur in some of the tissues that receive most of the RF
exposure from mobile phone use.
A secondary objective was to evaluate the relation be-
tween these tumours and a number of known and potential
risk factors, including ionising radiation, occupational
exposure to electromagnetic fields and the subject’s per-
sonal and familial medical history.
Methods
Sixteen study centres in thirteen countries (Australia;
Canada: Montreal, Ottawa, Vancouver; Denmark; Finland;
France; Germany; Israel; Italy; Japan; New Zealand; Nor-
way; Sweden; and the UK: North and South) participated
in INTERPHONE.
Source population
In Australia, Canada, France, Germany, Italy, Japan and
New Zealand, the source population was restricted to major
metropolitan areas where mobile phones were first intro-
duced (Table 1). Major treatment centres for the diseases
of interest are concentrated in these areas and most of the
population is unlikely to go out of the region for diagnosis
and treatment. In all study regions except Paris and Tokyo,
it is believed that 90 to 95% of the cases are diagnosed or
treated in the collaborating units (Web Annex Table 1) in
the study areas. For practical reasons, limiting the study
area to these populations also facilitated face-to-face
interviews. In Denmark, Finland, Israel, Norway and
Sweden the study was largely nationwide. The UK-South
study was restricted to the South East of England, urban
and rural, and the UK-North study encompassed both urban
areas and sparsely populated rural areas.
All residents in the study regions aged 30 to 59 were
eligible for the study; additional eligibility criteria, such as
citizenship and proficiency in the local language were
imposed in some study centres (Web Annex Table 1). The
choice of age-range aimed to maximise the likelihood of
exposure. Mobile phone use is a relatively new phenome-
non: until the late 1990’s mobile phone use was mainly
The INTERPHONE study: design, epidemiological methods, and description of the study population 649
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restricted to people in the age range most likely to use the
phones for business purposes [7].
Case eligibility and ascertainment
Eligible cases were all residents of the study region diag-
nosed during the study period with a confirmed first pri-
mary glioma, meningioma, or acoustic neurinoma. Eight
centres (Australia; Canada—Montreal, Ottawa and Van-
couver; Denmark; Israel; Italy; Sweden) also included
malignant parotid gland tumours. Because benign parotid
gland tumours may be treated in a very large number of
institutions, most centres found it logistically difficult to
ensure complete ascertainment, and only Canada–Ottawa,
Israel and Sweden included them. They will not be dis-
cussed in this paper. The ICD codes for the eligible diag-
noses are presented in Web Annex Table 2.
All diagnoses were either histologically confirmed or
based on unequivocal diagnostic imaging. In Australia and
Germany, only histologically confirmed tumours were in-
cluded. In Denmark cases found to have had any previous
cancer (excluding non-melanocytic skin cancer) were ex-
cluded.
Each centre established procedures for the rapid ascer-
tainment of cases from participating diagnostic and treat-
ment units, which was particularly important for glioma
patients, whose health can deteriorate quickly. Every effort
was made to maintain a close relationship with the units to
ensure that cases were not missed and that the required
authorisations were obtained from treating physicians when
necessary. Close monitoring of case ascertainment was
essential and all study centres, except Finland and Japan,
used one or more secondary source (including medical
archives, hospital discharge and billing files, and hospital
or regional cancer registries) to improve ascertainment
levels. Enrolment of cases through secondary sources often
implied longer delays in case ascertainment and conse-
quently lower participation.
Control eligibility and selection
Controls were randomly selected from the source popula-
tion. The sampling frame depended on the local situation
(Table 1). The study design called for controls to be indi-
vidually- or frequency-matched to cases, with the number
of controls varying according to the tumour type: 1 control
per case for brain tumours; 2 for acoustic neurinoma; and 3
for parotid gland tumours. In Germany, two controls were
selected for each brain tumour case. Controls were matched
on year of birth (within 5-year categories), sex and study
region.
Controls were individually matched to cases in Canada–
Ottawa, Vancouver; France, Israel, Japan, New ZealandT
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and UK-North. In the other centres, individual matching
was conducted post hoc, with cases being assigned controls
chosen to have been interviewed as close as possible in
time to the case, from among those who fit the matching
criteria.
Approach to subjects and informed consent
All cases for whom physician authorisation for contact had
been obtained and all controls were initially informed
about the study and asked to participate. The procedures
varied between centres (Web Annex Table 3), depending
on the requirements of local Ethics Review Boards. In
seven centres, the cases were initially approached by the
treating physician or a nurse for consent to be included in
the study. In other study centres approaches included: ac-
tive case ascertainment by the study staff followed by
physician authorisation to contact each case directly;
blanket approval to contact all eligible cases; or a mix of
the two. In all centres participants provided signed in-
formed consent.
Collection of information on individual study subjects
Whenever possible, consenting subjects were interviewed
face-to-face by trained interviewers using a computer-as-
sisted personal interview (CAPI) questionnaire. Only Fin-
land used a paper version of the questionnaire. In
exceptional cases, telephone interviews were conducted
with difficult-to-reach subjects. If subjects became too tired
or confused to complete the interview in one session a
second appointment was arranged; a partner or other family
member could assist in the interview. When the study
subject had died or was too ill to participate, a proxy
respondent was interviewed where this was possible and
permitted by ethics committees. In Australia and New
Zealand an abbreviated questionnaire was used for proxy
interviews. Controls who refused to participate in the study
were asked, whenever possible, to complete a short non-
respondent questionnaire in all centres, except in Denmark
and UK-South, in order to evaluate whether they differed
from participating controls. A small number of cases in
some centres also completed the non-respondent ques-
tionnaire. Detailed results of analyses of the non-respon-
dent questionnaires will be published separately.
The study questionnaire covered demographic factors,
mobile phone use (detailed below), use of other wireless
communication devices including cordless DECT tele-
phones, occupational exposures to EMF and other potential
confounders or risk factors for the diseases of interest
(including exposure to ionising radiation, smoking and the
subject’s personal and familial medical history). Specific
questions on exposure to loud noise and hearing loss were
asked of acoustic neurinoma cases and their controls (and
of all controls in centres using frequency matching).
History of mobile phone use
Detailed questions were asked of regular mobile phone
users, defined as those with an average of at least one call
per week for a period of 6 months or more, concerning
their history of phone use. A paper calendar was handed to
the subject. Together, the respondent and interviewer at-
tempted to identify each phone used (aided by show cards
with pictures of hundreds of models of mobile phones that
were compiled and updated during the course of the study)
and to reconstruct the time period during which it was
used. This provided the subject with a visual record of the
phone history when responding to the subsequent detailed
questions.
For each phone, detailed questions were asked about the
initial pattern of use, including network operator and
average number and duration of calls, and any subsequent
changes in use patterns. Questions were also asked about
the proportion of time the phones were used in urban,
suburban or rural settings, while stationary or moving in a
vehicle, how often the antenna was extended, and whether
headsets or hands-free kits were used, as these factors may
modify the RF output power of the phones. The side of the
head on which the phone was usually held (i.e. the later-
ality of phone use) and the handedness (left or right-han-
ded) of the subject were recorded.
Validation studies
Validation studies were conducted to assess the accuracy of
subjects’ recall of their history of mobile phone use. Short-
term recall was assessed in volunteer subjects using either
software modified phones or network operators’ records in
eleven countries [42]. Validation of medium- to long-term
recall of phone use in comparison with network operator
records was possible in three countries (Australia, Canada
and Italy) for cases and controls, while validation of short-
term recall was possible for some subjects in Denmark,
Israel, and Sweden. Detailed methods and results of these
studies will be published separately.
Information on socio-economic status (SES) and other
socio-demographic factors
Attained level of education was used as a proxy for SES.
As education systems and attained levels do not have a
direct correspondence from one country to another, coun-
try-specific options for responses were used and recoded
into one of two schemes as indicated in Web Annex
Table 6. The exception was Germany, where an algorithm
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developed by the German Epidemiological Association
was applied [43]. Marital status and, where appropriate,
education level of the spouse were also recorded.
Diagnostic information
Detailed diagnostic information was obtained from medical
records for all cases interviewed and for non-interviewed
cases in most study centres. This information included
anatomical location and side of the tumour and histopa-
thology, including whether benign, malignant or of
uncertain behaviour (Web Annex Table 2).
Localisation of brain tumours
Since intracranial RF energy deposition from mobile
phones is non-uniform, with most of the energy absorbed in
the vicinity of the phone, the probable location of the origin
of the brain tumours was identified so that the RF ‘‘expo-
sure’’ at that location could be evaluated. Neuro-radiolo-
gists in each centre reviewed radiological images (MRI and
CT scans) or records and recorded tumour location on a
generic 3-dimensional grid map of the human head, made
up of cubes 1 cm3 in size, which was developed for the
purpose. The details of this methodology will be published
separately.
Data quality assurance
The CAPI questionnaire included many checks: the se-
quence of questions was constrained with little opportunity
to skip questions and automatic range and consistency
checks were incorporated. After completion of the inter-
views, routine checks were performed on the data from all
centres both locally and centrally. Inconsistencies and
ambiguities were identified and resolved wherever possible.
Assessment of exposure from mobile phones
The study used two main approaches to characterising
exposure from mobile phones. The first depended only on
the history of use derived from questionnaire responses and
the second attempted to evaluate the amount of RF energy
absorbed in different areas of the brain.
In both approaches, exposure was calculated up to a
given reference date, which was set to the date of the
diagnosis of the case in each matched set. Evaluation of RF
energy absorption required the localisation of the tumour,
which was defined crudely in terms of the side of the head,
or lobe of the brain, or more precisely, from the exact
location of the tumour on the 3-dimensional grid. Exposure
for each control was estimated at the location of the tumour
of his/her matched case.
Exposure derived from mobile phone history
Indices of exposure, including cumulative call time, aver-
age call duration and cumulative number of calls, overall
and within specific time-windows, with and without use of
hands-free devices, were computed using the detailed
information reported by regular users.
Absorbed RF energy
The amount and distribution of RF energy absorption in the
head vary according to a number of factors, including the
type of telephone and network (frequency and type of
transmission: digital or analogue, continuous or discon-
tinuous, use of power control), as well as the subject’s
patterns of use of the phone. We developed and validated a
model to estimate exposure, assessing the relative impor-
tance of the different factors and testing the adequacy of
the proposed approach. The algorithm combines ques-
tionnaire responses with information on tumour location,
the distribution of the specific absorption rate (SAR) of RF
in the head and factors that modify the amount of RF en-
ergy emitted by the phone. This will be the subject of a
separate paper.
Missing data
To avoid exclusion of subjects with missing responses to
questions about mobile phone use (which might be more
frequent in cases and long-term users and hence lead to a
bias), rules were developed for the imputation of missing
data. Hierarchical rules were defined a priori, and the same
imputation procedure was applied to each pertinent in-
stance. For example, if the number or duration of calls
made during a specific time period was missing, but the
subject provided information for adjacent time periods, the
value was imputed as the average of the two adjacent
periods. When this information was not available, the im-
puted value was the median use of all other users, in the
same period and region [44, 45].
Analytical methods
The primary goals of the international analyses are to assess
whether use of mobile phones and exposure to RF fields
increase the risk of selected tumours. In devising analytic
strategies, the following features must be considered:
• Exposure (absorbed RF energy from the phone) is
highly localised;
• The prevalence of phone use has increased rapidly
during the course of the study;
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• If there is risk, most previous studies imply that it
would be of low magnitude on the relative risk scale;
• The mechanism for an effect, if there is one, is
unknown; the relevant exposure metric is therefore
uncertain.
The main analyses will be based on conditional logistic
regression for matched sets. This simplifies the assignment
of the reference date, laterality and ‘‘tumour location’’ for
the controls, which are important when analysing the ef-
fects of an exposure that is very localised. In addition, for
an exposure that increased rapidly during the course of the
study, and considering that subjects’ recall of their past
exposures may be influenced by their current and recent
use patterns, the matching ensures that cases and controls
have been interviewed relatively closely in time.
Results
Case ascertainment
The median delay between date of diagnosis and interview
for glioma cases was 3 months, ranging from less than
2 months in three centres to 14 months in Norway where
initial difficulties in the identification of cases were only
overcome at a later stage (Table 2). Delays for meningi-
oma were similar overall (not shown), although the median
in several centres was a little longer than for glioma. De-
lays for acoustic neurinoma and malignant parotid gland
tumours tended to be longer—overall median 6 months
and 9 months respectively: because of their generally good
prognosis, retrospective case ascertainment over a period
of one year was allowed for these tumour types to increase
the sample size.
The proportion of low to high-grade glioma cases
ascertained was quite consistent across most centres where
this could be determined: 66% high-grade and 28% low-
grade, with 6% unknown overall. Overall 1% of the men-
ingiomas were malignant and 5% of unknown behaviour.
This was consistent across all study centres (not shown).
Control recruitment
Table 3 shows the distribution of intervals between the
dates of interview of glioma cases and their matched
controls. The overall median interval was 2 months, but
varied by centre, ranging up to 6 months in Japan and
8 months in Israel. 72% of the controls were interviewed
within 6 months of their matched cases. The proportions
Table 2 Distribution of delays between diagnosis and interview—glioma cases only
Study Centre Number of cases Delay between diagnosis and interview (months)
Median Percentage of cases
–1 to 1 1 to 3 3 to 6 More than 6
Australia 301 4 1 41 30 29
Canada
Montreal 65 7 0 3 37 60
Ottawa 25 8 8 16 8 68
Vancouver 80 5 0 1 60 39
Denmark 181 2 15 50 19 16
Finland 178 0 75 16 4 4
France 94 2 32 30 14 24
Germany 256 0 69 6 5 20
Israel 180 3 19 27 18 36
Italy 118 6 15 15 19 50
Japan 60 1 42 40 12 7
New Zealand 84 4 0 27 58 14
Norway 180 14 16 2 7 75
Sweden 227 3 13 42 30 15
UK
North 429 2 5 62 20 13
South 307 4 2 27 34 37
Total 2,765 3 19 31 22 27
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were respectively 6% and 23% for interviews more than
6 months before, and more than 6 months after their mat-
ched cases. The former was very low (< = 4%) in the
study centres where individual matching was used.
Participation
Case participation varied considerably by tumour type and
by centre (Table 4). The overall participation was 65% for
glioma cases (ranging from 37% to 92%), 78% for
meningioma (ranging from 57% to 92%), 82% for acoustic
neurinoma (ranging from 70% to 100%) and 75% for
malignant parotid gland tumours (with a wide range based
on very small numbers).
Participation was calculated as the proportion of all
eligible ascertained cases that were interviewed. The
denominator includes cases whose physician denied au-
thorisation to contact them: 5% of glioma, 2% of menin-
gioma and acoustic neurinoma and 9% of malignant
parotid gland tumour cases. This proportion was relatively
small for most centres and in eight centres there were none
at all.
There was little difference between centres in partici-
pation of glioma cases according to grade of tumour: 67%
overall for cases with high-grade tumours and 71% for
cases with low-grade tumours.
Overall participation amongst controls was 53% (Ta-
ble 4) but showed large variation across centres, ranging
from 35% to 74%. Eight of the study centres achieved
control participation of 60% or higher. The major reasons
for non-participation were refusal (64% of non-partici-
pants) and inability to contact (27%).
Amongst cases there was very little difference in par-
ticipation by age except in women with glioma, where
participation in the older age group was noticeably lower.
Amongst controls there were slightly higher participation
rates amongst women than men (Table 5).
Type and location of interview
The vast majority of interviews (94% for glioma cases and
95% for controls) were conducted face-to-face; the
remaining interviews were conducted by telephone (Ta-
ble 6). In most centres the proportion of face-to-face
Table 3 Distribution of interval between the dates of interview of controls and of cases to which they are matched—glioma cases only
Study Centre Number of
casesa
Interval between interview of controls and date of interview of the cases to which they are matched (months)
Median Percentage of matched sets
More than 6 months
before case
1 to 6 months
before case
Within 1 month
of case
1 to 6 months
after case
More than 6 months
after case
Australia 297 0 11 10 35 28 16
Canada
Montreal 65 0 9 20 46 25 0
Ottawab 25 1 4 24 24 40 8
Vancouverb 80 3 1 6 17 51 24
Denmark 179 0 1 11 51 30 7
Finland 177 1 2 12 40 36 11
Franceb 94 4 1 0 6 60 33
Germany 256 3 11 10 9 48 22
Israelb 180 8 2 6 3 30 59
Italy 118 5 16 15 4 24 41
Japanb 60 6 0 2 2 47 50
New Zealandb 83 5 4 3 8 44 40
Norway 154 0 16 22 23 19 20
Sweden 222 1 3 14 31 34 18
UK
Northb 421 3 0 0 7 76 17
South 299 1 7 17 31 24 21
Total 2,710 2 6 10 21 41 23
a Only cases with matched controls are included
b Study centre with individual matching of controls to cases
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interviews was over 90%. However, in Italy and Norway
respectively 39% and 48% of case interviews and 65% and
46% of control interviews were conducted by telephone.
The patterns of telephone interviews amongst cases with
the other tumour types were very similar (not shown).
The overall proportion of proxy respondents for glioma
cases was 13%. This varied considerably across centres,
from 2% to over 40% (Table 6). A small proportion of
interviews was conducted with the study subject accom-
panied by another person. The proportion of proxy inter-
views was less than 2% for meningioma and even less for
acoustic neurinoma and parotid gland cases. As would be
expected, there were virtually no proxy respondents
amongst the controls except in New Zealand where proxy
interviews were conducted for the controls matched to
cases who could not be interviewed themselves.
Overall, 60% of the face-to-face interviews with glioma
cases were conducted at home, 33% in hospital, and 7%
elsewhere (Web Annex Table 4). This varied greatly: in
some centres, nearly all interviews were conducted at
Table 4 Distribution of all cases and controls ascertained and proportion interviewed by study centre
Study centre Glioma Meningioma Acoustic neurinoma Malignant parotid gland
tumours
Controls
No.
ascertained
No. (%)
Interviewed
No.
ascertained
No. (%)
interviewed
No.
ascertained
No. (%)
interviewed
No.
ascertained
No. (%)
interviewed
No. from
sampling
frame
No. (%)
interviewed
Australia 536 301 (56) 413 255 (62) 179 127 (71) 21 7 (33) 1,608 669 (42)
Canada
Montreal 101 65 (64) 71 48 (68) 41 33 (80) 13 9 (69) 391 234 (60)
Ottawa 38 25 (66) 18 15 (83) 21 17 (81) 6 6 (100) 259 180 (69)
Vancouver 134 80 (61) 45 31 (69) 41 34 (83) 19 13 (68) 680 239 (35)
Denmark 248 181 (73) 155 121 (81) 73 71 (97) 15 15 (100) 1,277 662 (52)
Finland 211 178 (84) 252 231 (92) 87 76 (87) –a – 1,337 559 (42)
France 155 94 (61) 190 148 (78) 140 111 (79) – – 639 472 (74)
Germany 312 256 (82) 275 250 (91) 76 67 (88) – – 1,869 1190 (64)
Israel 206 180 (87) 390 350 (90) 78 72 (92) 20 19 (95) 911 599 (66)
Italy 128 118 (92) 124 110 (89) 30 30 (100) 11 11 (100) 486 340 (70)
Japan 90 60 (67) 102 82 (80) 82 69 (84) – – 568 287 (51)
New Zealand 132 84 (69) 72 54 (75) 21 20 (95) – – 350 172 (49)
Norway 236 180 (76) 191 148 (77) 51 38 (75) 21 11 (52) 404 278 (69)
Sweden 298 227 (76) 205 184 (90) 107 102 (95) 20 18 (90) 617 407 (66)
UK
North 628 429 (68) 222 180 (81) 116 102 (88) – – 1,747 788 (45)
South 848 307 (37) 390 221 (57) 218 152 (70) – – 1,211 582 (48)
Total 4,301 2,765 (65) 3,115 2,425 (78) 1,361 1,121 (82) 146 109 (75) 14,354 7,658 (53)
a Parotid gland tumours were not included in these centres
Table 5 Participation rates amongst cases and controls by age and sex, all study centres combined
Number of cases ascertained and controls selected (% interviewed)
Age Glioma Meningioma Acoustic neurinoma Malignant parotid gland tumours Controls
Women Men Women Men Women Men Women Men Women Men
30–39a 398 (70) 565 (67) 313 (74) 109 (79) 139 (86) 156 (81) 21 (81) 14 (79) 1,601(54) 1,663 (48)
40–49 487 (70) 750 (68) 797 (78) 251 (76) 231 (81) 227 (80) 23 (83) 21 (62) 2,333 (58) 2,100 (51)
50–59a 816 (58) 1,285 (62) 1,239 (80) 406 (75) 325 (83) 283 (83) 26 (73) 41 (73) 3,573 (55) 3,084 (52)
Overall 1,701 (64) 2,600 (64) 2,349 (79) 766 (76) 695 (83) 666 (82) 70 (79) 76 (71) 7,507 (56) 6,847 (51)
a Note that controls may have been younger than 30 or older than 59 when matched to cases in the lowest or highest age groups
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home; in others, nearly all were in hospital. The distribu-
tion of interview location was similar for meningioma and
acoustic neurinoma cases (not shown). In contrast, 7% of
control interviews took place in hospital (mainly in Finland
and, to a lesser extent in Norway and Sweden, where study
subjects were invited to treatment institutions for inter-
view), 70% in the subject’s home and 22% elsewhere (Web
Annex Table 4).
Quality of interviews
After an interview had been completed the interviewer
recorded his or her impression of the reliability of infor-
mation on a 5-point scale, overall and for each specific
section. The percentage of subjects judged by the inter-
viewer to be unresponsive or uncooperative overall was
very low for both cases and controls (1.8 and 1.2%
respectively), ranging by centre from 0 to 5.6% among
glioma cases and up to 4.7% among controls. The per-
centages of cases and controls who were mobile phone
users and were judged by the interviewer to have had little
or no difficulty in remembering past phone use were 80, 86,
91 and 94%, respectively, among glioma, meningioma,
acoustic neurinoma and parotid gland tumour cases, and
91% among controls (not shown).
Interviews were conducted by 230 different interview-
ers, the number ranging from 2 in Canada–Montreal to 39
in Denmark. About 35% of the interviewers conducted less
than 20 interviews and 25% of the interviewers conducted
fewer than 10, mostly with cases. While 84% of the sub-
jects were interviewed by interviewers who had a balanced
workload between cases and controls, the workload in three
centres was particularly unbalanced (Web Annex Table 5).
Subjects available for analyses
Table 7 shows the number of cases and controls available
for analysis, as well as the total number of matched sets by
tumour type. Overall there were 2,765 glioma cases, 2,425
meningioma cases, 1,121 acoustic neurinoma cases, 109
malignant parotid gland tumour cases and 7,658 controls
available for analysis. A total of 55 glioma, 15 meningi-
oma, 17 acoustic neurinoma and 2 parotid gland tumour
cases were excluded from matched analyses due to a lack
of suitable controls. Conversely, 196 interviewed controls
could not be matched to any cases.
Table 6 Distributions of interviews by mode of interview and interviewee, for glioma cases and all controls
Study centre Total number of interviews Percentage of interviews that were
Mode of interview Interviewee
Face-to-face Telephone Subject alone or with another person Proxy
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Australia 301 669 99 98 1 2 86 100 14 0
Canada
Montreal 65 234 95 94 5 6 63 98 37 2
Ottawa 25 180 92 100 8 0 84 100 16 0
Vancouver 80 239 100 100 0 0 98 100 3 0
Denmark 181 662 100 100 0 0 94 100 6 0
Finland 178 559 99 99 1 1 97 100 3 0
France 94 472 97 88 3 12 89 100 11 0
Germany 256 1190 100 100 0 0 90 100 10 0
Israel 180 599 99 99 1 1 81 100 19 0
Italy 118 340 61 35 39 65 56 95 44 5
Japan 60 287 100 100 0 0 98 100 2 0
New Zealand 84 172 100 100 0 0 79 88 20 12
Norway 180 278 52 54 48 46 69 100 31 0
Sweden 227 407 94 94 6 6 93 100 7 0
UK
North 429 788 100 100 0 0 92 100 8 0
South 307 582 100 100 0 0 95 100 5 0
Total 2,765 7,658 94 95 6 5 87 99 13 1
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Missing data
About 10% of glioma cases and about 5% of the other
cases and of controls had some missing data concerning
their history of mobile phone use (Table 8). The percentage
varied across centres (ranging from 2.7 to 23.7% among
glioma cases and 0.7 to 13.8% among controls).
Socio-demographic factors
The proportion of subjects in the lowest educational level
was somewhat higher for cases than controls in several
centres (Web Annex Table 6). There were little differences
in marital status between cases and controls for all types of
tumour. Women were less likely than men to be married
(not shown).
Discussion
INTERPHONE is the largest case–control study of gli-
oma, meningioma, acoustic neurinoma and parotid gland
tumours to date. It was set-up to evaluate possible
associations between RF exposure from mobile tele-
phones and risk of these tumours. It focuses on mobile
phone use, by far the largest source of exposure to RF
fields in the general population. Comparing exposures
from mobile phones with the wide array of existing RF
devices is complicated because they depend, inter alia,
on the output power, the frequency of the field emitted
and proximity to the source. Sources at a distance, such
as radio-TV transmitters and base stations, imply low
levels of exposure [46]. Sources operated close to the
human body entail the highest levels of exposure [47].
Other wireless applications such as cordless phones or
wireless Internet (WLAN) systems are now very com-
mon; however, their peak output power is below the level
of typical mobile phones. Cordless telephones have an
average output power of the order of 10 mW for DECT
and less for other technologies [46], compared to about
120 mW for mobile phones operating in GSM 900 for
example.
In addition to providing information concerning risks
related to mobile phone use, INTERPHONE provides the
largest case–control source of data on other potential risk
factors for the tumours of interest including medical and
Table 7 Number of cases and controls available for analysis and number of matched case–control sets, by tumour type and study centre
Glioma Meningioma Acoustic neurinoma Malignant parotid gland
tumours
No.
cases
No.
controls
Matched
setsa
No.
cases
No.
controls
Matched
sets
No.
cases
No.
controls
Matched
sets
No.
cases
No.
controls
Matched
sets
Australia 301 669 297 255 669 253 127 669 127 7 669 7
Canada
Montreal 65 234 65 48 234 48 33 234 33 9 234 9
Ottawa 25 180 25 15 180 15 17 34 17 6 180 6
Vancouver 80 239 80 31 239 31 34 72 34 13 239 13
Denmark 181 662 179 121 662 124 71 425 70 15 662 15
Finland 178 559 177 231 559 231 76 559 75 –b
France 94 472 94 148 472 144 111 221 107 –
Germany 256 1190 256 250 1190 250 67 144 67 –
Israel 180 599 180 350 599 350 72 264 72 19 599 19
Italy 118 340 118 110 340 110 30 68 30 11 340 11
Japan 60 287 60 82 287 82 69 287 69 –
New Zealand 84 172 83 54 172 52 20 32 17 –
Norway 180 278 154 148 278 143 38 278 38 11 278 11
Sweden 227 407 222 184 407 184 102 361 102 18 251 16
UK
North 429 788 421 180 788 173 102 185 94 –
South 307 582 299 221 582 220 152 582 152 –
Total 2,765 7,658 2,710 2,425 7,658 2,410 1,121 4,415 1,104 109 3,452 107
a The case to control ratio is one to one for glioma and meningioma, one to two for acoustic neurinoma and one to three for parotid gland
tumours. Note that in Germany two matched controls were interviewed for each case of glioma and meningioma
b -Parotid gland tumours were not included in theses centres
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occupational exposure to EMF and to ionising radiation
and medical history of subjects and their families.
To the extent possible, we standardised the design,
procedures and materials across study centres. Some
methodological variation across centres was unavoidable,
however, in regard to approach to cases and controls, type
of interview and mode of interview. The varying con-
straints of ethical committees influenced the methods of
recruitment of cases and controls. In some centres quite a
large proportion of cases was ascertained late through
secondary sources. Because of this, a number of cases
(particularly glioma) had died or were too ill to be inter-
viewed and proxy respondents had to be found. A sub-
stantial proportion of interviews, particularly for controls,
was conducted by phone to increase participation in some
centres.
Case–control studies such as INTERPHONE are prone
to various possible sources of error. These include possible
selection bias related to non-participation amongst cases
and controls; random and differential error in recall of
mobile phone use; differences between cases and controls
in timing of interviews in a period of dramatic increase of
mobile phone use; and confounding by other potential risk
factors for these diseases.
Selection bias
The INTERPHONE study is no exception to the apparently
inexorable decline in participation rates amongst controls
selected from the general population for epidemiological
studies [48]. The source population is younger than in
many other cancer studies and at an age when response
rates tend to be lower. The youngest men proved particu-
larly difficult to recruit. Another factor influencing the
participation of controls is the difficulty of finding a sam-
pling frame with sufficiently accurate, up-to-date and
complete information, which resulted in large numbers of
subjects who could not be traced or could not be contacted
using the methods authorised by ethics committees.
The possibility that participation among controls might
be selective with respect to phone use was of concern,
given the low participation rate (53%). Mobile phone users
could be over-represented among non-participating sub-
jects as they may be more difficult to trace (fewer with
listed telephone numbers for land-lines) or too busy to
participate; this could lead to overestimation of the true
OR. Alternatively, we have some evidence from the non-
respondent questionnaires—which were completed by 57%
of controls who refused to participate and may not be
Table 8 Proportion of subjects in each study centre for whom missing mobile phone use data were imputed—by case–control status
Glioma Meningioma Acoustic neurinoma Malignant parotid
gland tumours
Controls
No.
cases
% With
imputed values
No.
cases
% With
imputed values
No.
cases
% With
imputed values
No.
cases
% With
imputed values
No.
controls
% With
imputed values
Australia 301 16.6 255 2.0 127 2.4 7 0.0 669 4.9
Canada
Montreal 65 12.3 48 2.1 33 0.0 9 0.0 234 4.3
Ottawa 25 4.0 15 0.0 17 5.9 6 0.0 180 1.1
Vancouver 80 3.8 31 9.7 34 0.0 13 0.0 239 4.6
Denmark 181 8.8 121 9.6 71 5.6 15 6.7 662 6.3
Finland 178 12.4 231 10.8 76 5.3 –a 559 13.8
France 94 9.6 148 2.8 111 3.6 – 472 4.7
Germany 256 2.7 250 1.6 67 0.0 – 1,190 1.7
Israel 180 10.6 350 4.0 72 5.6 19 10.5 599 6.7
Italy 118 23.7 110 5.5 30 10.0 11 0.0 340 9.7
Japan 60 6.7 82 1.2 69 5.8 – 287 0.7
New Zealand 84 6.0 54 0.0 20 0.0 – 172 1.7
Norway 180 9.4 148 6.1 38 7.9 11 0.0 278 5.8
Sweden 227 14.5 184 13.0 102 12.7 18 11.1 407 7.6
UK
North 429 7.9 180 2.2 102 2.0 – 788 3.4
South 307 12.1 221 2.7 152 5.3 582 6.4
Total 2,765 10.6 2,425 4.9 1,121 4.7 109 4.6 7,658 5.3
a -Parotid gland tumours were not included in these study centres
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representative of all non-participants in the study—that non
mobile phone users may be more likely to refuse to par-
ticipate, perhaps in the mistaken belief that non-users are of
no interest to the study [49]. Such a bias could artificially
increase the proportion of users among interviewed con-
trols and reduce the likelihood of finding an effect should it
exist. As ordained by local ethics committees, the presen-
tation of the study differed somewhat by centre. We esti-
mate that 41% of all controls were recruited in centres that
used an approach in letters and information material that
explicitly indicated that the primary objective concerned
mobile phones, 46% were recruited in centres that men-
tioned mobile phones, without highlighting them, and 13%
in the three centres that made no explicit mention of mobile
phones. Thus there is a potential for differential partici-
pation between users and non-users and between users by
level of use. The impact of a possible selection bias with
respect to controls has been evaluated in a simulation study
and shown to be potentially important [50]. Thus, it will
have to be taken into account in interpreting the INTER-
PHONE results. In particular, analyses will be conducted
by level of participation and by mode of presentation of the
study.
Selection bias with regard to severity of illness may also
arise in cases, particularly glioma cases. For example, as
would be expected from the poor prognosis and strong
impact on communication skills, the participation of gli-
oma cases (65%) was less than that of patients with
meningioma, acoustic neurinoma and malignant parotid
gland tumours (78, 82 and 75% respectively). If RF
exposure were related to the severity and prognosis of
cancer, differential participation due to severe illness, early
death or cognitive impairment could lead to bias. Despite
considerable effort to ensure rapid ascertainment to avoid
these difficulties, late ascertainment of a proportion of
cases because of logistic reasons and, in some countries
difficulties in complying with the requirements of ethics
committees, resulted in lower participation than expected.
Comparison of response by grade of tumour for gliomas,
however, shows no major difference across study centres
with different delays between diagnosis and interview. The
possibility of severity or survival bias will nevertheless
have to be considered when interpreting results.
Recall error
Self-reports of historical mobile phone use may be prone to
substantial error. If such errors occur randomly, they usu-
ally bias risk estimates towards the null (no effect). They
also increase the uncertainty of risk estimates, making it
more likely that real associations are not detected. Results
of short-term validation studies with volunteers indicate
that recall of phone use is subject to moderate systematic
error, but substantial random error: a substantial proportion
of subjects markedly over- or under-estimated their mobile
phone use [42].
Cases may spend time after the diagnosis of their tumour
trying to understand why they have developed this disease,
which might introduce a differential bias (sometimes re-
ferred to as rumination bias) in comparison with controls in
recall of the amount and side of phone use. In addition,
some of the patients with glioma might have recalled their
phone use less accurately because of severe illness or
cognitive impairment. Information about possible differ-
ences in recall of amount of use between cases and controls
was obtained from retrospective validation studies. Anal-
yses are underway and will be taken into account in the
interpretation of results. The results of these analyses will
be published separately.
Analyses of the INTERPHONE data will include vari-
ous approaches to examining the potential for recall bias
related to mobile phone use.
Other sources of bias
Possible confounding effects of region, age and sex will be
taken into account systematically by the matching of cases
and controls. Indeed, the mean ages of cases and controls
are very close (glioma cases and controls 47.3 years;
meningioma cases and controls 49.3 years; acoustic neu-
rinoma 47.5 and 47.7 years respectively for cases and
controls; parotid gland tumour cases and controls
46.3 years).
Because SES may well be correlated with mobile phone
usage and with brain cancer risk [51], our primary indicator
of SES, education status, will be included as a confounder
in the analyses.
A priori, we do not have strong grounds for believing
that other possible causes of the tumours studied, such as
family history of brain tumour, past medical radiation
exposure, smoking history and occupations in jobs with
potential for ionising and non-ionising radiation exposure,
would be related to mobile phone use. Nonetheless, the
possibility of confounding by these factors will be exam-
ined empirically and they will be included in risk models
where their inclusion results in a change in the ORs for the
mobile phone use variables of 10% or more [52].
The fact that controls tended to be interviewed later than
cases may also be a source of bias: because of the dramatic
increase of mobile phone use during the study period,
subjects interviewed later are more likely to have been
mobile phone users. This will be handled by the matching,
by truncating the exposure history of controls at the ref-
erence date, and, where appropriate, by adjustment of
analyses for dates of interview and by analyses restricted to
cases and matched controls interviewed close in time.
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Symptoms of the disease could affect the use of mobile
phones. Thus the year before diagnosis will not be included
in the exposure period, and control exposure time will be
truncated accordingly. For some tumours, however, early
symptoms may appear much earlier. This will need to be
considered carefully for acoustic neurinoma patients, as the
early symptoms comprise hearing loss, tinnitus or buzzing
sounds in the ear, which could lead patients to use mobile
phones less frequently or to change the side of use.
There is also concern about the possibility of bias due to
differences between cases and controls and between short
term and long-term users in the extent of missing infor-
mation and imputations for missing values were therefore
conducted. Sensitivity analyses will be conducted exclud-
ing subjects with imputations, telephone and proxy inter-
views, and study subjects who were judged by the
interviewer to be uncooperative or to remember their phone
use poorly.
Differential assignment of cases and controls to inter-
viewers in some centres and the use of many interviewers
who conducted few interviews may be another potential
source of bias. Sensitivity analyses will be conducted
excluding interviewers with fewer than 20 interviews and
those who interviewed nearly exclusively cases or controls.
Finally, despite the fact that INTERPHONE was jointly
planned and based on a common core protocol, there was
some heterogeneity in the methods used. Sensitivity anal-
yses will be conducted excluding, in turn, different study
centers. Additional analyses of patterns of results across
study centres are planned to evaluate, in particular, the
impact of the way the study was presented (whether a study
of mobile phone use or a more general study) and of the
participation levels among cases and controls. These will
be helpful in addressing the potential for bias that might
affect the overall findings.
Conclusions
Large, carefully conducted multi-centric international
studies are an important source of information for the
elucidation of the possible impact of mobile phone usage
on cancer risk. This paper describes the complex methods
used as well as the methodological hurdles that we have
encountered. Particular attention was paid to errors and
biases resulting from selection and non-participation of
eligible subjects and from reporting of mobile phone usage.
Different types of sub-studies were conducted to inform the
analysis and interpretation of results.
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